These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33136501)

  • 21. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
    Parasrampuria S; Sen AP; Anderson GF
    Am J Manag Care; 2020 Sep; 26(9):388-394. PubMed ID: 32930551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Has The Era Of Slow Growth For Prescription Drug Spending Ended?
    Aitken M; Berndt ER; Cutler D; Kleinrock M; Maini L
    Health Aff (Millwood); 2016 Sep; 35(9):1595-603. PubMed ID: 27605638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis drugs in the medicare population: dermatologists' spending and prescription patterns.
    Yang JJ; Pham AT; Maloney NJ; Aly O; Cheng K
    J Dermatolog Treat; 2022 May; 33(3):1758-1761. PubMed ID: 33307894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Payments For Opioids Shifted Substantially To Public And Private Insurers While Consumer Spending Declined, 1999-2012.
    Zhou C; Florence CS; Dowell D
    Health Aff (Millwood); 2016 May; 35(5):824-31. PubMed ID: 27140988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing prescription drug sector: new expenditure methodologies.
    Genuardi JS; Stiller JM; Trapnell GR
    Health Care Financ Rev; 1996; 17(3):191-204. PubMed ID: 10158730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medicaid Spending on Antiretrovirals From 2007 Through 2019.
    Walsh BS; Kesselheim AS; Rome BN
    Clin Infect Dis; 2023 Mar; 76(5):833-841. PubMed ID: 36268585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.
    McCormick N; Wallace ZS; Sacks CA; Hsu J; Choi HK
    Arthritis Rheumatol; 2020 Feb; 72(2):234-241. PubMed ID: 31609057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-gap discounts in Medicare Part D and specialty drug use.
    Jung J; Xu WY; Cheong C
    Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
    Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
    BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
    Trish E; Xu J; Joyce G
    Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
    LaVange LM; Silverman HA
    Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the Effects of Pioneer Accountable Care Organizations on Medicare Part D Drug Spending and Utilization.
    Zhang Y; Caines KJ; Powers CA
    Med Care; 2017 May; 55(5):470-475. PubMed ID: 28060052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
    Rome BN; Patel AN; Kesselheim AS
    Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
    Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
    Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do Medicare Advantage Rebates Reduce Enrollees' Out-of-Pocket Spending?
    Nicholas LH; Wu S
    Med Care Res Rev; 2020 Oct; 77(5):474-482. PubMed ID: 30382801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending?
    Seeley E; Kesselheim AS
    Issue Brief (Commonw Fund); 2017 Sep; 2017():1-8. PubMed ID: 28953345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010-2016.
    McRae J; Vogenberg FR; Beaty SW; Mearns E; Varga S; Pizzi L
    Pharmacoeconomics; 2017 Feb; 35(2):215-223. PubMed ID: 27798809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.